Latest News and Press Releases

Alumis Completes Merger with ACELYRIN

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

Alumis has strengthened its leadership team with CCO and CLO to support its transition to a late-stage company.

In a Phase 1 trial, oral TYK2 inhibitor A-005 was well tolerated and demonstrated ability to cross blood-brain barrier; Phase 2 to start in MS in 2H 2025.

Data at ACR for ESK-001, oral TYK2 inhibitor, demonstrates potential as a high efficacy oral for treatment of Systemic Lupus Erythematosus (SLE).

Alumis reports third quarter 2024 financial results, highlights positive data and near term milestones for its ongoing clinical programs.

Alumis CEO will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference on Tues Nov 12 at 2:00 pm ET

Late breaking research presentation at EADV shows increasing and sustained responses in 28-week Phase 2 data for ESK-001 in psoriasis

Alumis will be participating in several investor conferences in September